President Trump's Marijuana Fix? DEA's Program Exposed: Promises Made, Promises Not Kept
WASHINGTON, D.C. / / August 17, 2025 / President Trump's decision to potentially reschedule marijuana is the first serious step in decades to break through the bureaucratic logjam that has kept patients and scientists waiting. For years, the DEA has promised a functional marijuana research program. For years, those promises have been broken.
DEA's Promises on Paper
In its Final Rule (85 Fed. Reg. 82333, Dec. 18, 2020), the DEA pledged that marijuana manufacturing licenses would be tied to FDA science and genuine medical research. The agency declared:
"DEA will evaluate each application… to determine whether the applicant's proposed activities… will promote medical research."
"DEA will require applicants to demonstrate bona fide supply agreements with researchers authorized by the FDA to conduct clinical research."
"DEA's goal is to ensure that the United States has a sufficient supply of marihuana to meet the legitimate medical, scientific, and research needs of the United States."
These were the promises.
The Harsh Reality
But DEA's actions told a different story:
Licenses granted to companies with no FDA INDs, no clinical trial protocols, and no scientific foundation.
No bona fide supply agreements with FDA-authorized researchers - a direct violation of DEA's own Final Rule.
Four years later, there is still no adequate, federally compliant supply of cannabis for clinical trials, leaving patients with Huntington's Disease, Multiple Sclerosis, and other conditions waiting.
The only company that meets DEA's own published criteria - MMJ BioPharma, with two FDA-filed INDs and an Orphan Drug Designation - has been stalled while non-scientific registrants received licenses.
Promises Made, Promises Not Kept
DEA's marijuana program has been a case study in mismanagement:
Rules written, then ignored.
Patients promised access, then denied it.
Science promised priority, then sidelined.
President Trump's possible rescheduling decision shines a spotlight on this failure. By moving marijuana to Schedule III, he has forced the issue back into the open and made clear that real reform will require DEA accountability.
The Path Forward
Patients deserve more than empty promises. They deserve consistent, reproducible, FDA-approved medicines. They deserve agencies that follow their own rules. And they deserve leadership that keeps its word.
With rescheduling now on the table, it is time to hold DEA to account for the gap between its promises and its performance. President Trump has taken the first step - now the DEA must be compelled to deliver.
MMJ is represented by attorney Megan Sheehan.
CONTACT:Madison HiseyMHisey@mmjih.com203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Zelensky returns to site of stunning Oval Office shouting match
Ukrainian President Volodymyr Zelensky returns to the Oval Office on Monday for the first time since a spectacularly tense exchange with Donald Trump saw their talks cut short and question marks raised over future US support. At the February 28 meeting, Trump and Vice President JD Vance berated Zelensky on live television, accusing him of being ungrateful for US aid provided since Russia's invasion three years prior, and pressing for quick negotiations to end the war. The hostile confrontation marked a turning point in Kyiv-Washington relations, which had been warm under former president Joe Biden, and raised fears that Trump would cut off US military support. The scene quickly devolved at the end of a long question-and-answer session with the press. Vance accused Zelensky of being "disrespectful" and displaying ingratitude for Trump's diplomatic efforts, after the Ukrainian leader expressed skepticism that Russian President Vladimir Putin could be trusted given his repeated violations of earlier agreements. As Zelensky defended his position in his non-native English, Trump was enraged by the Ukrainian leader's suggestion that while the United States was currently far from the fighting, "you will feel it in the future" if they appeased Putin. "You don't know that. You don't know that. Don't tell us what we're going to feel. We're trying to solve a problem. Don't tell us what we're going to feel," railed Trump, before adding: "You're not in a good position. You don't have the cards right now." As tempers flared, Vance demanded Zelensky thank the United States for the billions provided to Kyiv in military aid. "Have you said 'thank you' once?" he asked. When Zelensky attempted to respond, he was silenced by Trump. "No, no. You've done a lot of talking. Your country is in big trouble," said Trump, cutting Zelensky off. The Ukrainian leader left the White House shortly after, without signing a mineral rights deal that was a key reason for his visit. In the ensuing days, the United States temporarily cut off military aid and intelligence sharing with Ukraine, heightening European fears that Trump would side with Putin in trying to end the conflict. - Shifting tides - Much water has since flowed under the bridge, however. Trump, who has in the past expressed his admiration for Putin, began to lose patience with the Russian leader, as Moscow kept up its military offensive even as US special envoy Steve Witkoff engaged in feverish diplomacy to achieve a ceasefire. In April, Trump met with Zelensky at the Vatican, and accused Putin of "tapping me along" without delivering on promises. Days later, Ukraine and the United States finally signed a minerals deal, which Trump had earlier referred to as compensation for US aid. The two leaders also met face-to-face in June on the sidelines of the NATO summit at The Hague. On Friday, Trump met with Putin in Alaska to discuss the Ukrainian conflict, promising to run any proposals by both Ukraine and its European allies before agreeing to a deal. Shortly after the Putin summit, Trump invited Zelensky to the Oval Office. Perhaps wary of the contours of the previous diplomatic dust-up, Zelensky quickly said he was "grateful for the invitation." European leaders will join Zelensky in Washington on Monday, seeking above all else to prevent another Oval Office meltdown -- but also to coordinate on the path toward peace negotiations, especially on how to prevent any future Russian invasion. On the latter front, the Trump administration says it is now open to providing Ukraine security guarantees, a shift hailed Sunday by Ukrainian and European leaders. Zelensky is expected to first meet one-on-one with Trump, before they are joined by European leaders, including UK Prime Minister Keir Starmer, French President Emmanuel Macron, German Chancellor Friedrich Merz, NATO Secretary-General Mark Rutte and EU chief Ursula von der Leyen, a European government source said. According to US broadcaster CNN, Zelensky's former sparring partner -- Vice President Vance -- will also be present. aha/des
Yahoo
8 hours ago
- Yahoo
Qualys (QLYS) Wins Two Pwnie Awards at DEF CON for Groundbreaking OpenSSH Vulnerability Research
Qualys, Inc. (NASDAQ:QLYS) is one of the Qualys, Inc. (NASDAQ:QLYS) is one of the best midcap AI stocks to buy right now. On August 12, 2025, Qualys announced that its Threat Research Unit (TRU) received two Pwnie Awards at the DEF CON cybersecurity conference for its groundbreaking work uncovering critical OpenSSH vulnerabilities. The awards, 'Epic Achievement' and 'Best Remote Code Execution (RCE)', recognized Qualys for identifying CVE-2024-6387, the first pre-authentication RCE in OpenSSH in nearly two decades, and CVE-2025-26465, a man-in-the-middle attack affecting FreeBSD clients. The wins cement Qualys' status as a major player in vulnerability research. welcomia/ Alongside its ongoing threat research, Qualys expanded coverage within its Enterprise TruRisk Platform on August 12, 2025, issuing new vulnerability checks tied to Microsoft's latest Patch Tuesday update. While the company did not publish a formal press release, its research portal listed 98 vulnerabilities across 12 Microsoft security bulletins, with immediate support deployed for customer environments. The update underscores Qualys' operational emphasis on rapid detection and remediation, reinforcing its reputation for delivering same-day protections aligned with major vendor disclosures. Qualys is a U.S.-based provider of cloud-native IT, security, and compliance solutions. Its platform is used by global enterprises to manage vulnerabilities, ensure policy compliance, protect against threats, and inventory digital assets across hybrid environments. While we acknowledge the potential of QLYS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
SentinelOne (S) Expands Mimecast Partnership to Advance Human-Centric Cybersecurity
SentinelOne, Inc. (NYSE:S is one of the SentinelOne, Inc. (NYSE:S) is one of the best midcap AI stocks to buy right now. On August 6, 2025, SentinelOne announced an expanded partnership with Mimecast to advance human-centric cybersecurity. The integration connects SentinelOne's Singularity™ Platform with Mimecast's Human Risk Management (HRM) solution, enabling enterprises to correlate endpoint telemetry with behavioral insights and email-based threat intelligence. The goal is to strengthen real-time detection, automate risk scoring, and deliver targeted awareness training based on individual user behavior. Den Rise/ This collaboration marks a shift toward more adaptive, user-aware security frameworks. By analyzing how people interact with their environments, through devices, apps, and communications, the combined solution helps identify at-risk users and prioritize them for intervention. SentinelOne's AI-driven endpoint protection feeds into Mimecast's analytics to uncover patterns of risky behavior, enhancing both detection and prevention efforts. SentinelOne is a California-based cybersecurity company that provides autonomous endpoint protection, cloud security, and identity threat detection through its Singularity™ Platform. The company employs artificial intelligence and machine learning to deliver real-time threat prevention, detection, and response at machine speed. While we acknowledge the potential of S as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and .
